Ei­dos, Avro­bio shoot for $201M as biotech IPOs con­tin­ue to roll for­ward on Nas­daq

Just a few weeks af­ter RA Cap­i­tal’s high-pro­file part­ner Ra­jeev Shah signed up to lead a $64 mil­lion round for San Fran­cis­co-based Ei­dos Ther­a­peu­tics, Bridge­Bio’s start­up fo­cused on TTR amy­loi­do­sis, the biotech is out of the IPO chute in search of $115 mil­lion or more. And they are right on the heels of an­oth­er start­up on the East Coast, Avro­bio, join­ing the lat­est wave of new ar­rivals to try their luck and sci­ence on Wall Street.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.